Research
& development

The heart of VaxThera is research and development. Through innovation and excellence in our biotechnological processes, we aim to save lives and improve the quality of life for people.

As a Colombian company, VaxThera understands firsthand what our territory needs, and based on that knowledge, we will deliver leading-edge technology solutions to the country.

In our research and development pipeline, we are focusing on the development of vaccines and therapies against emerging, re-emerging, and tropical neglected diseases that are prevalent in certain areas of Latin America:

Human pipeline

Research
Headquarters

820 m²
15 Researchers
Modern Technologies: mRNA
and vectors
Knowledge Generation
Good Laboratory Practices (GLP)

Thanks to the technology and quality of our laboratory facilities, at VaxThera, we will have the capability to conduct rigorous research studies, design, produce, and validate vaccine candidates, optimize production processes, and generate high-quality vaccines and biologics for use in preclinical studies.

Ongoing Projects

UniVax

We have developed a universal vaccine against SARS-CoV-2 using a viral vector platform. The vaccine has shown, in preclinical stages, to be safe, immunogenic, and effective against various virus variants. This vaccine is currently undergoing evaluation to initiate clinical trials.

Colombian Ministry of Science, Technology, and Innovation

Vaccines against Zika, chikungunya, and yellow fever are being developed through a partnership with the University of Wisconsin and the Universidad Nacional de Colombia, funded by the Colombian Ministry of Science, Technology, and Innovation. Our goal is to develop and evaluate the vaccines up to the preclinical level, using two technological platforms: viral vector and mRNA.

United States Department of Agriculture (USDA)

In partnership with the University of Wisconsin - Madison, we are currently evaluating our universal COVID-19 vaccine (UniVax) to limit virus transmission in multiple animal species and reduce the risk of transmission to humans. Additionally, we are working on developing a formulation that allows the vaccine to be administered orally or intranasally while maintaining its protective properties.

Research Team

At VaxThera, we are committed to transparency and quality in our research. This is why, as a company and research team, we are registered on SCIENTI, the platform of the Colombian Ministry of Science, Technology, and Innovation, aiming to establish connections with other companies in the sector to enhance the ecosystem.